Moderna (MRNA) soared a further 16% in Tuesday’s after-market trading after the biotech announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19.Results reaffirmed positive interim data assessment announced on May 18, said Moderna, and show mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2. Neutralizing antibodies were observed in 100% of evaluated participants at the 100 µg dose level selected for the upcoming Phase 3 trial.Published in The New England Journal of Medicine, the interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart across three …read more
Source:: Yahoo Finance
